再生元制药公司在一份提交给美国证券交易委员会的文件中披露,一项知识产权研发相关费用预计将导致该公司2026年第三季度GAAP和非GAAP每股收益均减少0.18美元。
再生元制药公司在一份提交给美国证券交易委员会的文件中披露,一项知识产权研发相关费用预计将导致该公司2026年第三季度GAAP和非GAAP每股收益均减少0.18美元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.